← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Aug 31, 2026

AMARIN CORP PLC\UK (AMRN)

Healthcare • NASDAQ

$13.97

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

16.0/100

POOR BUSINESS

AMARIN CORP PLC\UK (AMRN) scores 16/100 — concerning metrics indicating significant structural or financial risks.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full AMRN quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full AMRN valuation analysis · → View full AMRN Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-6.0%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.03x)

Operating Margin (Operational Efficiency):CRITICAL (-21.9%)

Return on Capital (Capital Efficiency):CRITICAL (-9.8%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

AMARIN CORP PLC\UK (AMRN) stock report — Zyberno Score 16/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:13.97

Market Cap:$292.36M

Valuation Multiples (3)

P/B Ratio:0.66x

P/S Ratio:1.57x

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$162.02M

Price Action & Momentum (3)

12-1 Momentum:

-3.9% (34th pctile)

📈 Click to view full AMRN Momentum analysis →

Momentum Percentile:34 / 100

% of 52-Week High:66.8%

B. Profitability Assessment

Return Metrics (5)

ROE:

-6.0%

📊 Click to view full AMRN ROE analysis →

ROA:-4.2%

Roic:

-9.8%

📊 Click to view full AMRN ROIC analysis →

Reinvestment Rate:9.9%

Fundamental Growth Rate (g):-1.0%

Margin Analysis (3)

Operating Margin Ttm:-21.9%

Net Margin Ttm:-14.6%

Ebitda Margin:-17.9%

TTM Performance (3)

Gross Margin Ttm:42.0%

Operating Margin Ttm:-21.9%

Net Margin Ttm:-14.6%

Yield Metrics (2)

Earnings Yield:-$1.00

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):

+0.14

📊 Click to view full AMRN Earnings Surprise analysis →

EPS Surprise vs Expected:43.9%

Latest Earnings Filed:2026-07-29

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-17.7%

Cash Flow Growth (Linear) (1)

Operating Cash Flow Growth Rate (Linear):50.2%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.67x

Quick Ratio:2.67x

Cash Ratio:0.87x

Leverage Analysis (3)

Debt To Equity Ttm:0.03x

Debt-to-Equity Ratio:0.03x

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-7,167.14x

Times Interest Earned:-7,167.14

Capital Structure (4)

Working Capital:438,563,000.00

Cash And Cash Equivalents:143,558,000.00

Long Term Debt:$11.30M

Net Debt:-$130.34M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $186.23M

Linear Growth: -17.7%

📊 Click to view full AMRN Revenue analysis & methodology →

Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

Gross profit TTM: $78.13M

Linear Growth: -25.5%

📊 Click to view full AMRN Gross Profit analysis & methodology →

-$40.77M

Bottom Line Performance (3)

-$27.12M

Income Before Tax:-$25.56M

Ebitda Ttm:-33,369,000.00

Operating Expenses (5)

Operating Expenses:118,908,000.00

R And D Expense:19,017,000.00

Sga Expense:83,058,000.00

Income Tax Expense:$1.56M

Interest Expense:7,000.00

Expense Ratios (3)

R And D To Revenue Percentage:45.1%

Sga To Revenue Percentage:196.8%

Ebitda Margin:-17.9%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$624.36M

Current Assets:$602.76M

Ppe Net:12,000.00

Goodwill:0.00

Intangible Assets:$12.09M

Liability Structure (4)

Total Liabilities:180,747,000.00

Current Liabilities:164,195,000.00

Long Term Debt:$11.30M

Short Term Debt:$1.92M

Equity & Capital (3)

Equity:$443.62M

Retained Earnings:-$1.73B

Common Stock:314,531,000.00

Working Capital Items (3)

Accounts Receivable:92,917,000.00

Inventory:164,073,000.00

Accounts Payable:18,796,000.00

Special Items (2)

Contract Liabilities:0.00

Stock Based Compensation:2,331,000.00

C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: $25.58M

Linear Growth: 50.2%

$0.00

Investment Activities (1)

Investing Cash Flow:-$8.30M

Financing Activities (3)

Financing Cash Flow:-$1.69M

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:440,108,000.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:7,405,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.14

-$0.14

Earnings Per Share Ttm:-$1.30

Revenue & Cash Per Share (2)

Sales Per Share Ttm:8.90

Operating Cash Flow Per Share:$0.32

Book Value & Capital (2)

Book Value Per Share:$21.20

Cash Per Share:6.86

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.29x

Working Capital Turnover Ttm:0.42x

Receivables Management (2)

Receivables Turnover Ttm:2.00x

Days Sales Outstanding Ttm:182.11

Inventory Management (2)

Inventory Turnover Ttm:1.14x

Days Inventory Outstanding Ttm:321.57

Payables & Cash Cycle (2)

Days Payable Outstanding:36.84

Cash Conversion Cycle:466.84

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00

Quality Score:50.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:9.9%

Fundamental Growth Rate (g):-1.0%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-17.7%

Cash Flow Growth Rates (1)

Operating Cash Flow Growth Rate (Linear):50.2%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-25.5%

Book Value Growth Rate (Linear):-8.0%

C. Company Profile & Context

Corporate Information (6)

Symbol:AMRN

Company Name:AMARIN CORP PLC\UK

Sector:Healthcare

Industry:Pharmaceuticals

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:medium

Volume Category:N/A

Share Structure (3)

Shares Outstanding:20.93M

Shares Outstanding Basic:416.44M

Shares Outstanding Diluted:416.44M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-08-31 00:02:40 UTC

Data Timestamp:2026-08-18T05:10:45.812991